Exact Mass: 374.0894
Exact Mass Matches: 374.0894
Found 37 metabolites which its exact mass value is equals to given mass value 374.0894,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N-Desmethylzopiclone
N-Desmethylzopiclone is a metabolite of Eszopiclone. Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic which is slightly effective for insomnia. Eszopiclone is the active dextrorotatory stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrolones. (Wikipedia)
Ethyl gallate 3-glucuronide
Ethyl gallate 3-glucuronide belongs to the class of organic compounds known as hydrolyzable tannins. These are tannins with a structure characterized by either (1) galloyl units (in some cases, shikimic acid units) that are linked to diverse polyol carbohydrate-, catechin-, or triterpenoid units, or (2) at least two galloyl units C-C coupled to each other and without a glycosidically linked catechin unit. Ethyl gallate 3-glucuronide is an extremely weak basic (essentially neutral) compound (based on its pKa).
Ethyl gallate 4-glucuronide
Ethyl gallate 4-glucuronide belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans and flavonoids. Ethyl gallate 4-glucuronide is an extremely weak basic (essentially neutral) compound (based on its pKa).
Syringic acid glucuronide
3-(6-((4-(Trifluoromethoxy)phenyl)amino)pyrimidin-4-yl)benzamide
(4-Methoxyphenyl)-morpholin-4-yl-morpholin-4-ylsulfanyl-sulfidophosphanium
(5E,11E,15E,19E)-20-bromoeicosa-5,11,15,19-tetraen-9,17-diynoic acid|(all-E)-form-20-Bromo-5, 11, 15, 19-eicosatetraene-9, 17-diynoic aicd
3-[3-Fluoro-4-(4-morpholinyl)phenyl]-5-[[(methylsulfonyl)oxy]methyl]-2-oxazolidinone
(R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate
(S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine
6,8-difluoro-4-methyl-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
n-Hydroxy-4-[(4-methoxylphenyl)sulfonyl]-2,2-dimethyl-hexahydro-1,4-thiazepine-3(s)-carboxamide
[(2R,3S,4R,5S)-3,4-dihydroxy-5-(5-methoxy-6-methylbenzimidazol-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
3-Tert-butyl-7-[[2-(4-methylphenyl)-2-oxoethyl]thio]-[1,3,4]thiadiazolo[2,3-c][1,2,4]triazin-4-one
3-Hydroxy-2-[5-[4-(trifluoromethyl)phenyl]-2-furanyl]-1,2-dihydroquinazolin-4-one
2-(4-chlorophenyl)-N-[(Z)-pyrrol-2-ylidenemethyl]cinchoninohydrazide
1-butyl-3-thiophen-2-ylsulfonyl-2H-imidazo[4,5-b]quinoxaline
6-[(1H-benzimidazol-2-ylthio)methyl]-1-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4-one
BMS-984923
BMS-984923, a potent mGluR5 silent allosteric modulator (SAM), with exquisite binding affinity (Ki = 0.6 nM), exhibits good oral bioavailability and BBB penetration. BMS-984923 potently inhibits the PrPC-mGluR5 interaction and prevents pathological Aβo signaling without affecting physiological glutamate signaling[1][2].
